Highlights

• Imugene received AUD 2,145,157 under Australia’s Research and Development tax incentive.

• The refund will help recruit patients in azer-cel’s Phase 1b trial.

• Cohort 3 assesses azer-cel alongside Bruton tyrosine kinase inhibitor treatment.

• September-quarter operating cash outflow totalled AUD 7.49 million.

Imugene Limited (ASX:IMU), an Australian clinical-stage developer of cancer immunotherapies, received an AUD 2,145,157 research and development tax refund for FY26. The company said the payment would support recruitment in Cohort 3 of its Phase 1b basket study of azer-cel, an off-the-shelf CAR T-cell therapy targeting CD19-expressing blood cancers. The refund arrives as Imugene continues clinical development following a September 2026 quarter in which it reported AUD 7.49 million of net operating cash outflows and AUD 5.25 million in closing cash.

How the Tax Refund Supports Research

The Australian Government’s R&D Tax Incentive provides eligible businesses with offsets linked to qualifying research expenditure. Imugene’s FY26 refund is a Cash Receipt related to eligible prior spending, rather than Revenue generated by commercial medicine sales. That distinction is important for interpreting the funding event. The company indicated the refund would assist patient recruitment in its current clinical programme. It can contribute to study expenditure without itself demonstrating that the treatment is effective or approved. Further financing needs depend on future operating expenditure, fundraising and the scope of continuing clinical activities.

The Azer-cel Clinical Programme

Azer-cel, also called azercabtagene zapreleucel, is an allogeneic CAR T-cell therapy manufactured using donor-derived immune cells. Its CD19 target is associated with certain B-cell cancers. Cohort 3 of the Phase 1b basket study is evaluating use alongside Bruton tyrosine kinase inhibitors, which are targeted treatments used in B-cell malignancies. The study includes patients with difficult-to-treat disease who have previously received therapies including BTK inhibitors. Early-stage response reporting can inform further research, but it does not establish comparative efficacy or the risk-benefit profile required for regulatory approval.

September-Quarter Financial Context

Imugene’s quarter-ended 30 September 2026 cash-flow report recorded net operating cash outflow of AUD 7.49 million, a reduction of 19% from the prior quarter. The company also disclosed AUD 5.25 million in cash at quarter-end, before receipt of the R&D refund. It reported AUD 11.12 million raised before costs through a two-tranche Placement and changes to convertible-note arrangements. These figures show why Cash Management remains central for a developer without an approved commercial product from the azer-cel programme. The tax refund supplements funding but should not be mistaken for recurring operating revenue.

What Clinical Data Can Establish

Imugene’s October Quarterly Report included response data from the Phase 1b programme, including Cohort 3 and another patient group. Such data are relevant to ongoing trial design, but the number of participants, follow-up periods and study design all affect interpretation. A Phase 1b trial commonly examines safety, dosing and preliminary activity rather than demonstrating the outcomes of a larger confirmatory study. Future disclosures on recruitment, durability of responses, safety events and additional cohorts will provide more context. Regulatory authorisation and broader use would require separate evaluation; neither follows automatically from a tax refund or interim responses.

Key Insights

The AUD 2.145 million refund returns part of eligible research expenditure and supports continued patient recruitment. Imugene’s operating cash flows and available Capital remain separate considerations. Azer-cel is still in clinical evaluation, and any assessment of progress should distinguish reported preliminary response observations from evidence of lasting benefit and eventual regulatory approval.